Parallel Trades - Strategy - We Suggest Going
To ensure rupee neutral strategy, we suggest going long on DIVISLAB with 1 lot(s) and going short on AARTIIND with 1 lot(s)
335 Views
Divi’s Laboratories - Miss in 2QFY23; Growth Factors to Face Softness over Medium Term
DIVI delivered an earnings miss in 2QFY23. Reduced traction in Custom Synthesis (CS), coupled with lower operating leverage resulted in an earnings...
339 Views
Custom Synthesis/Nutraceuticals drive earnings growth
DIVI delivered in line 2QFY22 earnings led by strong offtake in the Custom Synthesis (CS) segment and ramp up in the Nutraceuticals segment. It has...
125 Views
DIVISLAB: DIVI delivered in line 4QFY21 earnings
DIVI delivered in line 4QFY21 earnings. It ended FY21 on a strong note, with 29%/57%/54% YoY growth in sales/EBITDA/PAT. New product development,...
176 Views